The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

(2021) Erin F. Cobain et al.   JAMA Oncology

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

(2019) David Malka et al.   EUROPEAN JOURNAL OF CANCER

Phase I study of capmatinib in MET‐positive solid tumor patients: dose escalation and expansion of selected cohorts

(2019) Yung‐Jue Bang et al.   CANCER SCIENCE

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors

(2018) Eric Van Cutsem et al.   CLINICAL CANCER RESEARCH

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET ONCOLOGY

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Daniel V T Catenacci et al.   LANCET ONCOLOGY

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

(2017) Manish A. Shah et al.   JAMA Oncology

Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach

(2016) J. Lee et al.   CLINICAL ONCOLOGY

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

(2016) Nick Pavlakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Equal access to innovative therapies and precision cancer care

(2016) Agnès Buzyn et al.   Nature Reviews Clinical Oncology

Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

(2011) Francesco Graziano et al.   JOURNAL OF CLINICAL ONCOLOGY

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY